Is the price fair?
What COR's price assumes
Cencora trades at 24.3× earnings against 31.5× for the median Healthcare name, cheaper than its own group.
24.3
Trailing P/E · Healthcare median 31.5 · cheaper than the typical name in its group
- Price / sales
- 0.19
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.7%
Free cash flow yield · Healthcare median 4.7%
- Growth the price implies
- −0.05%
Growth the price implies · The price pays for −0.05% free cash flow growth a year for a decade; the business has delivered +13% a year over the last three.
Details›
- Price / book2026-Q1
- 18.0
- EV / EBIToperating margin 0.91%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.22
- Healthcare median P/E362 names
- 31.5
- Free cash flow, trailing twelve months
- $4.06B
- Market capitalisation
- $52.9B
- 3-year revenue growth
- +9.4%
- 3-year free cash flow growth
- +13%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $213.90 |
| Its own P/E history, median | $270.53 |
| Its own P/E history, upper quartile | $326.80 |
| 52-week range | $252.16 – $373.25 |
| Today | $327.73 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.